Corticobasal Degeneration clinical trials at University of California Health
2 research studies open to eligible people
4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2
open to eligible people ages 40-80
The goal of this study is to identify the most reliable methods of analysis for tracking CBD, PSP, and o/vPSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug trials. The study will also provide information about the relative value of novel imaging techniques for diagnosis, as well as the value of imaging techniques versus testing of blood, urine, and cerebrospinal fluid (CSF) 'biomarkers'.
at UCSD UCSF
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
open to eligible people ages 18 years and up
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
at UCLA UCSD UCSF
Our lead scientists for Corticobasal Degeneration research studies include Adam L Boxer, MD, PhD Howie Rosen, MD.